drugset / Trial / NCT05903703
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
Not yet recruiting
20 enrolled
Zhang Xiaofeng,MD
College of Pharmaceutical Sciences at Zhejiang University · collabThe Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Gemcitabine-based chemotherapy or combination with FOLFIRINOX is the leading treatment of pancreatic cancer. However, the overall response rate of pancreatic cancer to gemcitabine is less than 20%. Resistance to gemcitabine is the most important reason. There is an urgent need to develop new combination therapies to improve the efficiency of chemotherapy, avoid toxicity limitations, and improve the overall prognosis of pancreatic cancer. At present, it has been found that canagliflozin can reduce the expression level of PD-L1 in pancreatic cancer and restore the vitality of CD8+ T cells. Canagliflozin combined with gemcitabine may improve the efficiency of chemotherapy.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2026-09-30
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANAGLIFLOZIN ANHYDROUS | Small molecule | 125 mg | Oral |
| Subject | CANAGLIFLOZIN ANHYDROUS | Small molecule | 400 mg | Oral |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |